UnitedHealth Drops Descovy as Generic Shakes Up PrEP Class

UnitedHealthcare is dropping coverage in its commercial plan formularies for Gilead Sciences, Inc.’s HIV pre-exposure prophylaxis (PrEP) medication Descovy (emtricitabine and tenofovir alafenamide), steering patients instead to Gilead’s Truvada (emtricitabine/tenofovir disoproxil fumarate) as a generic version of Truvada is set to launch.

Other plans are likely to follow suit in their PrEP formularies when Teva Pharmaceutical Industries Ltd. releases its generic version of Truvada on Sept. 30, one industry insider says. But formularies could be shaken up again in 2021 as an “A” rating from the U.S. Preventive Services Task Force (USPSTF) for PrEP takes effect, requiring plans to provide health plan members at high risk of HIV with access to PrEP without copayments or deductibles.

© 2021 MMIT

Freelance Reporter Freelance Reporter

Related Posts

https://www.mmitnetwork.com/wp-content/uploads/2021/09/Drug_Benefits_Life_Sciences.jpg
November 23

Will ‘Build Back Better’ Spell Disaster for Pharma Innovation?

READ MORE
https://www.mmitnetwork.com/wp-content/uploads/2021/11/WordPress-Featured-Image-health-plan-weekly-Wall-Street-Isnt-Sweating-Cignas-Third-Quarter-MLR-Miss.jpg
November 23

Big Three PBMs’ 3Q Results Make Up for Insurer Disappointments

READ MORE
https://www.mmitnetwork.com/wp-content/uploads/2021/11/WordPress-Featured_AdobeStock_442155384.jpg
November 23

SCAN Health Opts to Invest in Medication Adherence Tool

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today